Roche's Rituxan halves risk of lymphoma recurrence | Reuters
Links shared publicly online about this topic.
- 1,154total visits
Roche's Rituxan halves risk of lymphoma recurrence | Reuters
View full resource at reuters.com
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Drug, Pharma, Rituxan
Most Recently Shared on May 21, 2010 at 1:15 am By:
Study: Roche's Rituxan halves risk of follicular lymphoma recurrence http://bit.ly/c6iFyw - #health #pharma
UPDATE 1-Roche's Rituxan halves risk of lymphoma recurrence | Reuters
reuters.com — “* Risk of relapse reduced 50 percent after 2 years * Cancer progressed in 18 pct of Rituxan patients (Adds comments, price details) By Deena Beasley LOS ANGELES, May 20 (Reuters) - Continued use” View full resource at reuters.com
Most Recently Shared on May 21, 2010 at 1:35 pm By:
Big News for fNHL pts: stdy shows Rituxan maintenance therapy cuts recurrence rate in half. http://bit.ly/cpex5y
Roche's Rituxan halves risk of lymphoma recurrence | Reuters
reuters.com — “LOS ANGELES (Reuters) - Continued use of Rituxan, a drug sold by Roche Holding AG and Biogen Idec Inc, reduced by about 50 percent the chance that follicular lymphoma patients would have their cancer return,” View full resource at reuters.com
Most Recently Shared on May 20, 2010 at 6:08 pm By:
Roche's Rituxan halves risk of lymphoma recurrence: LOS ANGELES (Reuters) - Continued use of Rituxan,... http://bit.ly/9O2Lgz #health #news
Roche's Rituxan halves risk of lymphoma recurrence | Reuters
reuters.com — “LOS ANGELES (Reuters) - Continued use of Rituxan, a drug sold by Roche Holding AG and Biogen Idec Inc, reduced by about 50 percent the chance that follicular lymphoma patients would have their cancer return,” View full resource at reuters.com
Most Recently Shared on May 20, 2010 at 6:06 pm By:
Roche's Rituxan halves risk of lymphoma recurrence http://link.reuters.com/gux45k
Advertisement
